Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinoma

Fig. 4

PFS and OS of patients receiving the different treatments. (A) OS of patients with MVI positive. (B) OS of patients with MVI positive; (C)OS of patients with MVI negative; (D) PFS of patients with MVI negative; (E) OS of patients with interval of recurrence from initial treatment ≥ 1 year; (F) PFS of patients with interval of recurrence from initial treatment ≥ 1 year; (G)OS of patients with interval of recurrence from initial treatment <1 year; (H) PFS of patients with interval of recurrence from initial treatment <1 year. MVI, microvascular invasion

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us